Brokerages Anticipate Eagle Pharmaceuticals Inc (EGRX) to Post $0.72 Earnings Per Share

Analysts expect Eagle Pharmaceuticals Inc (NASDAQ:EGRX) to post earnings per share (EPS) of $0.72 for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Eagle Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at $0.71 and the highest estimate coming in at $0.73. Eagle Pharmaceuticals reported earnings per share of $0.95 during the same quarter last year, which would suggest a negative year-over-year growth rate of 24.2%. The firm is scheduled to report its next earnings report on Tuesday, August 6th.

On average, analysts expect that Eagle Pharmaceuticals will report full year earnings of $3.43 per share for the current year, with EPS estimates ranging from $3.38 to $3.50. For the next financial year, analysts expect that the firm will post earnings of $4.11 per share, with EPS estimates ranging from $3.10 to $5.11. Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that cover Eagle Pharmaceuticals.

Eagle Pharmaceuticals (NASDAQ:EGRX) last posted its quarterly earnings data on Tuesday, May 7th. The specialty pharmaceutical company reported $1.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.28. The company had revenue of $49.80 million for the quarter, compared to analyst estimates of $47.03 million. Eagle Pharmaceuticals had a net margin of 17.67% and a return on equity of 21.38%. The business’s quarterly revenue was up 6.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.55 earnings per share.

EGRX has been the topic of several research analyst reports. Zacks Investment Research raised Eagle Pharmaceuticals from a “hold” rating to a “buy” rating and set a $49.00 target price on the stock in a research note on Friday, January 18th. ValuEngine cut Eagle Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, February 13th. BidaskClub raised Eagle Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, February 23rd. Cantor Fitzgerald reissued a “hold” rating and issued a $58.00 target price on shares of Eagle Pharmaceuticals in a research note on Thursday, February 28th. Finally, Royal Bank of Canada set a $66.00 target price on Eagle Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, March 1st. Five analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $65.17.

Shares of EGRX traded down $1.09 during mid-day trading on Wednesday, reaching $54.79. 183,077 shares of the stock traded hands, compared to its average volume of 204,686. The firm has a market capitalization of $774.06 million, a P/E ratio of 26.22 and a beta of 1.67. Eagle Pharmaceuticals has a 12-month low of $36.03 and a 12-month high of $85.66. The company has a quick ratio of 3.89, a current ratio of 4.12 and a debt-to-equity ratio of 0.21.

In other Eagle Pharmaceuticals news, Director Douglas L. Braunstein sold 159,223 shares of the firm’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $56.81, for a total value of $9,045,458.63. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Scott Tarriff sold 24,975 shares of the firm’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $50.15, for a total transaction of $1,252,496.25. Following the completion of the sale, the chief executive officer now owns 1,500,202 shares of the company’s stock, valued at $75,235,130.30. The disclosure for this sale can be found here. Insiders sold 208,626 shares of company stock worth $11,547,936 over the last three months. 28.20% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently modified their holdings of EGRX. Park West Asset Management LLC boosted its holdings in Eagle Pharmaceuticals by 41.6% in the fourth quarter. Park West Asset Management LLC now owns 1,050,000 shares of the specialty pharmaceutical company’s stock worth $42,304,000 after purchasing an additional 308,574 shares during the period. Vanguard Group Inc raised its holdings in shares of Eagle Pharmaceuticals by 9.7% during the third quarter. Vanguard Group Inc now owns 674,951 shares of the specialty pharmaceutical company’s stock worth $46,794,000 after purchasing an additional 59,474 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Eagle Pharmaceuticals by 9.7% during the third quarter. Vanguard Group Inc. now owns 674,951 shares of the specialty pharmaceutical company’s stock worth $46,794,000 after purchasing an additional 59,474 shares during the last quarter. D. E. Shaw & Co. Inc. raised its holdings in shares of Eagle Pharmaceuticals by 121.5% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 285,318 shares of the specialty pharmaceutical company’s stock worth $11,495,000 after purchasing an additional 156,499 shares during the last quarter. Finally, Millennium Management LLC grew its position in Eagle Pharmaceuticals by 2,385.0% during the fourth quarter. Millennium Management LLC now owns 284,753 shares of the specialty pharmaceutical company’s stock valued at $11,473,000 after buying an additional 273,294 shares during the period. Institutional investors and hedge funds own 94.36% of the company’s stock.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL); and Belrapzo, a chemotherapeutic agent for CLL and Indolent NHL.

See Also: Bond

Get a free copy of the Zacks research report on Eagle Pharmaceuticals (EGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.